Skip to content

Halozyme Therapeutics HALO Derivative Assets, Non-Current

Derivative Assets, Non-Current at other companies

Chord Energy logo
Chord EnergyCHRD
$3.52M-28.2%
SM Energy logo
SM EnergySM
$27M+664%
Kodiak Gas Services logo
Kodiak Gas ServicesKGS
$6.58M-43.4%
Iris Energy logo
Iris EnergyIREN
$192M
Antero Resources logo
Antero ResourcesAR
$50.81M+6,431%
Hut 8 Mining Corp. logo
Hut 8 Mining Corp.HUT
$161.7M

Other financials

Income statement

See full
Revenue$376.7M+42.2%
Gross profit$297.5M+37.4%
Operating income$184.5M+30.4%
Net income$150.0M+27.1%
EPS (diluted)$1.22+31.2%

Balance sheet

See full
Cash & equivalents$312.0M+76.9%
Total debt$2.2B+41.7%
Total equity$219.6M-54.5%
Total assets$2.7B+21.7%

Cash flow

See full
Operating cash flow$180.1M+16.8%
CapEx$3.7M+294%
Free cash flow$176.3M+15.0%

Valuation

See full
Market cap$8.13B-2.9%
Enterprise value$10B+3.0%
P/E13.4×-3.8×
P/S5.4×-2.3×

Profitability

See full
Gross margin82.8%-0.7pp
Operating margin59.3%+9.0pp
Net margin47.9%+6.5pp
FCF margin44.3%-1.5pp

Returns & leverage

See full
Return on equity124.5%+12.7pp
Debt / equity9.9×+6.7×
Current ratio2.8×-5.6×

Where this comes from

Reported directly by Halozyme Therapeutics in its filing.

Tagged under the XBRL concept us-gaap:DerivativeAssetsNoncurrent.

The official record: Halozyme Therapeutics’s 10-Q, filed May 11, 2026, on SEC EDGAR. View the filing →

Ask your AI about Halozyme Therapeutics's derivative assets, non-current.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Halozyme Therapeutics's derivative assets, non-current?
Halozyme Therapeutics (HALO) reported derivative assets, non-current of 30,000,000% in Q1 2026.
How has Halozyme Therapeutics's derivative assets, non-current changed year-over-year?
Halozyme Therapeutics's derivative assets, non-current decreased by 50.0% year-over-year, from 60,000,000% to 30,000,000%.